ArticleAmerican journal of ophthalmology case reports2026
Topical losartan to prevent stromal scarring during post-cross-linking infection in pediatric keratoconus: A case report.
Article in American journal of ophthalmology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paediatric Keratoconus: An ERN-EYE Clinical Consensus Statement on Diagnosis, Treatment and Follow-Up Care.Ophthalmology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report a pediatric case of post-corneal cross-linking (CXL) infectious keratitis successfully managed with early initiation of topical losartan to prevent corneal haze and stromal fibrosis. Case report: A 14-year-old boy developed infectious keratitis in the right eye two days after undergoing bilateral epithelium-off CXL for advanced keratoconus. Slit-lamp examination revealed a mid-peripheral ring-shaped stromal infiltrate with overlying epithelial defect, edema, and posterior fibrin. Intensive empirical antimicrobial therapy was initiated. Off-label topical losartan 0.08% was started at twice a day on day 4 post-CXL to mitigate fibrotic remodeling. The infection resolved without complications, and 0.08% topical losartan was progressively increased to four times a day for a total duration of three months. Stromal clarity improved significantly over the following weeks, with no adverse effects or recurrence in the following three months after cessation of the losartan. Conclusions and importance: This case demonstrates that early topical losartan can be safely administered in the acute phase of post-infectious keratitis in a pediatric patient. Although early use appeared to limit scar formation, the presence of a residual central corneal scar and reduced visual acuity precludes any conclusions regarding its effectiveness in improving visual outcomes. These findings suggest that timely antifibrotic therapy may influence corneal healing, but controlled studies are needed to define its efficacy, optimal timing, and dosing in both pediatric and adult populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.